Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Natera, Inc. $103.5 Million Follow-On Public Offering
Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000…
Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering
Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to…
Forty Seven, Inc. $112.6 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035…
Magenta Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100…
Aptinyx Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of…
Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock,…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock…
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $2.05 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to…
Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility
Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in…